Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenstrom macroglobulinemia and CLL/SLL. Izutsu K, Ishikawa T, Shimada K, Kubo K, et al. Int J Hematol 2025;121:483-493.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Izutsu K, Ishikawa T, Shimada K, Kubo K, et al. Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenstrom macroglobulinemia and CLL/SLL. Int J Hematol 2025;121:483-493.
PMID: 39960615